The Accreditation Committee of the College of American Pathologists (CAP) has awarded
accreditation to ADmit Therapeutics, Barcelona, Spain based on results of a recent on-site
inspection as part of the CAP’s Accreditation Programs. Recognized for rigorous and robust
standards, CAP accreditation elevates quality and mitigates risk, an important way that
laboratories can contribute to improved patient outcomes. ADmit Therapeutics is a
biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical
Research Institute (IDIBELL). The company is focused on the development and
commercialization of a new early detection technology for Alzheimer’s disease
ADmit Therapeutics is one of more than 8,000 CAP-accredited facilities worldwide. The
facility’s director, Marta Blanch, PhD, was advised of this global recognition and congratulated
for the excellence of the services being provided. “By obtaining CAP accreditation, we
guarantee that our laboratory meets the highest global standards for quality. This achievement
not only validates our commitment to advancing scientific research, but also ensures the
reliability and accuracy of our services in the prognosis of progression from Mild Cognitive
Impairment to Alzheimer’s Disease Dementia” said Dr. Marta Blanch.
Dr. Marta Barrachina, CEO of the company, upon learning of the laboratory’s accreditation,
said: “This accreditation verifies the accuracy and reliability of our entire testing process and
demonstrates the huge effort done by our team. I would like to highlight the excellent work of
our Quality Manager, Victor Fuentes, and our Laboratory Director, Dr. Marta Blanch.
Moreover, we are very proud of becoming the first CAP-accredited laboratory in Spain”.
During the CAP accreditation process, designed to ensure the highest standard of care for all
laboratory patients, inspectors examine the laboratory’s records and quality control of
procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities,
safety program and record, and overall management. These reviews help verify activities and
reflect the most recent best practices.
With over 23,000 laboratory participants, in addition to accreditation, the CAP offers
proficiency testing/external quality assessment (PT/EQA) programs, quality improvement
tools, and protocols and guidelines to ensure excellence in all areas across the laboratory. Built
on a foundation of pathologist expertise, the College of American Pathologists (CAP) partners
with laboratories worldwide to elevate the quality of laboratory medicine with best-in-class
solutions designed to drive operational excellence, achieve diagnostic confidence, and ensure
the best patient care.
The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.
IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).